EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bioactivity-Guided Fractionation of Dragon’s Blood Phenolic Extracts Reveals Loureirin D as a P2Y12 Inhibitor Mediating Antiplatelet Effects

Jiawen Peng, Peng Wang, Ying Chen, Xin Liao, Hui Guo, Pei Zhang, Jiange Zhang

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms27010282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jiawen Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medici…. Hauptthemen laut MEDLINE: Plant Extracts, Platelet Aggregation Inhibitors, Receptors, Purinergic P2Y12, Purinergic P2Y Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Science and Technology Development Foundation, National Key Research and Development Program of China, Shanghai Municipal Administration of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dragon’s Blood, from the Dracaena cochinchinensis plant, is known for enhancing blood circulation. Its main components are Dragon’s Blood phenolic extracts (DBE). To pinpoint the active DBE constituents that are effective against thrombosis and understand their mechanism of action, the PT-stroke model was employed to assess DBE’s antithrombotic effects on cerebral blood flow and platelet aggregation. This investigation demonstrates that DBE enhances cerebral blood flow and inhibits ADP-induced platelet aggregation in photothrombotic (PT) stroke models. An FeCl3-induced carotid artery thrombosis model was developed to test the antithrombotic activity of four DBE fractions. Through screening with this model, the ethyl acetate (EA) and methanol fractions were identified as the principal active components that effectively reduced thrombus weight and improved hemodynamics. Furthermore, the EA fraction was found to preserve the integrity of the blood–brain barrier. Phytochemical isolation allowed for the identification of compounds in the EA fractions, and UHPLC-MS was performed to characterize DBE and its active components in the bloodstream. In vitro ADP-induced platelet aggregation assays highlighted the active compounds. Through phytochemical analysis, Loureirin D (compound 17) was identified as a predominant constituent present in plasma. In vitro assays revealed that compounds 1 and 17 possess strong antiplatelet activity, with Loureirin D being confirmed as a selective P2Y12 receptor antagonist via molecular docking and cellular thermal shift assays. These findings substantiate Loureirin D as a pivotal antithrombotic component in DBE and its potential as a P2Y12-targeting therapeutic agent for thrombosis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plant ExtractsPlatelet Aggregation InhibitorsReceptors, Purinergic P2Y12Purinergic P2Y Receptor AntagonistsDracaenaPhenolsAnimalsPlatelet AggregationMiceThrombosisMolecular Docking Simulation

Stichwörter der Autor:innen

ADPP2Y12ischemic strokeplatelets aggregationthrombosis

Substanzen

Plant ExtractsPlatelet Aggregation InhibitorsReceptors, Purinergic P2Y12dragon's bloodPurinergic P2Y Receptor AntagonistsPhenols

Autor:innen und Institutionen

  • The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
  • School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China.
  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.

Förderung

  • Shanghai Science and Technology Development Foundation
  • National Key Research and Development Program of China
  • Shanghai Municipal Administration of Traditional Chinese Medicine

Zitieren

APA

Peng, J., Wang, P., Chen, Y., Liao, X., Guo, H., Zhang, P., & Zhang, J. (2025). Bioactivity-Guided Fractionation of Dragon’s Blood Phenolic Extracts Reveals Loureirin D as a P2Y12 Inhibitor Mediating Antiplatelet Effects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010282

Vancouver

Peng J, Wang P, Chen Y, Liao X, Guo H, Zhang P, et al. Bioactivity-Guided Fractionation of Dragon’s Blood Phenolic Extracts Reveals Loureirin D as a P2Y12 Inhibitor Mediating Antiplatelet Effects. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010282

BibTeX
@article{Peng2025,
  author = {Peng, Jiawen and Wang, Peng and Chen, Ying and Liao, Xin and Guo, Hui and Zhang, Pei and Zhang, Jiange},
  title = {Bioactivity-Guided Fractionation of Dragon’s Blood Phenolic Extracts Reveals Loureirin D as a P2Y12 Inhibitor Mediating Antiplatelet Effects},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms27010282}
}
Kostenlos starten →